Rapid response to selpercatinib in RET fusion positive pancreatic neuroendocrine carcinoma confirmed by smartwatch

• Published in: NPJ precision oncology Vol. 8; no. 1; pp. 167 - 6
• Main Authors: Deschler-Baier, Barbara, Krebs, Markus, Kroiss, Matthias, Chatterjee, Manik, Gundel, Daniel, Kestler, Christian, Kerscher, Alexander, Kunzmann, Volker, Appenzeller, Silke, Maurus, Katja, Rosenwald, Andreas, Bargou, Ralf, Gerhard-Hartmann, Elena, Venkataramani, Vivek
• Format: Journal Article
• Language: English
• Published: London Nature Publishing Group UK 31.07.2024; Nature Publishing Group; Nature Portfolio
• Subjects: 692/308/409; 692/308/53; Cancer Research; Case Report; Case reports; Gene Therapy; Human Genetics; Inhibitor drugs; Internal Medicine; Medicine; Medicine & Public Health; Neuroendocrine tumors; Oncology; Pancreatic cancer; Smartwatches; Wearable computers

This case report describes the efficacy of selpercatinib, a selective RET inhibitor, in an unusual case of large-cell neuroendocrine pancreatic carcinoma (LCNEPAC) harboring a CCDC6 :: RET fusion. A 56-year-old male with a history of multiple lines of systemic therapies exhibited marked clinical ame...